

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
13/NW/0153	104669	CIPHER: Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases	Number Agreed	9	9	31/12/2017	4	31/12/2017	4	Recruitment Finished	Rare patient group study to close UK wide due to complexity and rarity of eligible patients
16/WM/0473	213847	CA209-817 - Nivolumab and Ipilimumab in advanced malignancies	Number Agreed	3	3	10/10/2020	6	21/11/2017	6	Recruitment Finished	Recruitment finished early UK wide, closed by Sponsor
15/EE/0353	187464	PCYC-1137: A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine,	Number Agreed	3	3	18/12/2017	2	18/12/2017	2	Recruitment Finished	Rare patient group
13/NW/0702	128871	ABC-06: ASC alone or with mFOLFOX for advanced biliary tract cancer	Number Agreed	10	10	30/11/2017	18	31/12/2017	18	Recruitment Finished	Target exceeded by CCC
15/SC/0521	185323	ABOUND.2L: A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nabpaclitaxel (Abraxane) with epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced nonsqua	Number Agreed	2	2	30/09/2017	16	31/12/2017	16	Recruitment Finished	Target exceeded by CCC
16/NE/0142	202233	JAVELIN OVARIAN 100: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER	Number Agreed	5	5	10/07/2017	2	19/01/2018	2	Recruitment Finished	Rare patient group, difficulty in patient uptake to this study
15/LO/1487	172859	RELAY: CANC - 3889 - Erlotinib + Ramucirumab or Placebo in Mutation-Positive Metastatic NSCLC	Number Agreed	6	6	31/08/2020	0	24/01/2018	0	Withdrawn By Sponsor	Sponsor closed study - all spaces for the EU & US regions have been taken
15/WA/0464	197094	VOCS: Investigation of biological changes in urine in patients with advanced lung cancer: a pilot study	Number Agreed	25	25	06/02/2018	15	06/02/2018	15	Recruitment Finished	CRN RP left the post, there was no replacement provided by the NWCRN therefore recruitment capacity was impeded. The study was opened at CCC on the understanding that this support would be provided.
13/NW/0842	137245	FAKTION: A phase 1b/2 randomised placebo controlled trial of fulvestrant +/-AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.	Number Agreed	4	4	31/03/2019	4	26/02/2018	4	Recruitment Finished	Sponsor closed early as recruitment target was reached CCC reached the target and the study closed ahead of planned time